Health & Fitness
Mon, October 1, 2012
MELVILLE, N.Y.--([ BUSINESS WIRE ])--Bovie Medical Corporation (the aCompanya) (NYSE MKT: BVX), a manufacturer and marketer of electrosurgical products and its new J-Plasmaa" system, today announced that the Company will present at the 2012 SeeThru Equity Fall Smallcap and Microcap Conference Tuesday, October 2, 2012 at 11:20am ET, at The Cornell Club 6 East 44th Street New York City, New York.
Investors will be able to access a replay of the presentation within 24 hours on the Companyas website [ www.boviemed.com ] or SeeThruEquityas website [ www.seethruequity.com ] for the next 90 days.
Cautionary Note on Forward-Looking Statements
Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.
Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Companyas ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Companyas filings with the Securities and Exchange Commission including the Companyas Report on Form 10-K for the year ended December31, 2011. For forward-looking statements in this new release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
For further information about the Companyas current and new products, please refer to the Investor Relations section of Bovieas website [ www.boviemed.com ].
